Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 4/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13674315 | 1.00 | MEN1 (0.59) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL3229154 | 1.00 | MEN1 (0.59) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL14725831 | 0.94 | MEN1 (0.54) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL19014890 | 0.94 | MEN1 (0.54) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL1786140 | 0.91 | MEN1 (0.69) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL4453290 | 0.91 | MEN1 (0.69) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| Biphenyl SCHEMBL9450695 | 0.85 | SCN1A (0.67) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL3233565 | 0.84 | MEN1 (0.61) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL1896141 | 0.84 | MEN1 (0.61) | MEN1KMT2ACHRNA7HTR3EHTR3B | |
| SCHEMBL1894674 | 0.84 | MEN1 (0.61) | MEN1KMT2ACHRNA7HTR3EHTR3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039930-A1 | PROLINE AMIDE COMPOUNDS AND THEIR AZETIDINE ANALOGUES CARRYING A SPECIFICALLY SUBSTITUTED BENZYL RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-06 | — | — | US | disclosed |
| EP-3601255-A1 | PROLINE AMIDE COMPOUNDS AND THEIR AZETIDINE ANALOGUES CARRYING A SPECIFICALLY SUBSTITUTED BENZYL RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018175449-A1 | PROLINE AMIDE COMPOUNDS AND THEIR AZETIDINE ANALOGUES CARRYING A SPECIFICALLY SUBSTITUTED BENZYL RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-09-27 | — | — | WO | disclosed |
| US-8637576-B2 | Benzamide derivatives and uses related thereto | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637576-B2 | Benzamide derivatives and uses related thereto | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637576-B2 | Benzamide derivatives and uses related thereto | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-1904435-B1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC (US) | 2013-01-02 | — | — | EP | disclosed |
| US-20100069447-A1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | AMGEN INC. | 2010-03-18 | — | — | US | disclosed |
| US-7605289-B2 | Benzamide derivatives and uses related thereto | AMGEN, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605289-B2 | Benzamide derivatives and uses related thereto | AMGEN, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | AMGEN INC. | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039930-A1 | PROLINE AMIDE COMPOUNDS AND THEIR AZETIDINE ANALOGUES CARRYING A SPECIFICALLY SUBSTITUTED BENZYL RADICAL | HTR2C, HTR2A, HTR5A | MEN1 4305/4885KMT2A 2028/4885CHRNA7 1141/4885 |
| US-20060293392-A1 | Benzamide derivatives and uses related thereto | GPR119, GLP1R, UGT2B7 | MEN1 2543/4885KMT2A 1365/4885CHRNA7 2306/4885 |
| US-20100069447-A1 | BENZAMIDE DERIVATIVES AND USES RELATED THERETO | GPR119, GLP1R, UGT2B7 | MEN1 2543/4885KMT2A 1365/4885CHRNA7 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.